Storia in 2 fonti

Bayer acquires Perfuse Therapeutics

Bayer has acquired Perfuse Therapeutics, including the full rights to the PER-001 intravitreal implant, which is in development for glaucoma and diabetic retinopathy.

Raccontata da

healio.com

morningstar.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo2 mesi fa

Bayer acquires Perfuse Therapeutics

Bayer has acquired Perfuse Therapeutics, including the full rights to the PER-001 intravitreal implant, which is in development for glaucoma and diabetic retinopathy.

originale

morningstar.com2 mesi fa

Bayer Completes Acquisition of Perfuse Therapeutics

Leggi questa versione → originale

Timeline cronologica

mercoledì 17 giugno 2026·healio.com
Bayer acquires Perfuse Therapeutics
Bayer has acquired Perfuse Therapeutics, including the full rights to the PER-001 intravitreal implant, which is in development for glaucoma and diabetic retinopathy.
mercoledì 17 giugno 2026·morningstar.com
Bayer Completes Acquisition of Perfuse Therapeutics
Bayer Completes Acquisition of Perfuse Therapeutics